DC-expressed MHC class I single-chain trimer-based vaccines prime cytotoxic T lymphocytes against exogenous but not endogenous antigens

Research output: Contribution to journalArticle

5 Scopus citations

Abstract

The poor immunogenicity of many tumors can be partly explained by the inefficiency of the MHC class I peptide presentation pathway. MHC-I-based single-chain trimers (SCT) represent a new class of molecules with the potential to overcome this limitation. We here evaluated the ability of SCT presenting a melanoma antigen peptide (TRP-2) to prime cytotoxic T lymphocyte (CTL) responses in mice when given as DNA vaccines via Gene Gun or when expressed by dendritic cells. The SCT was unable to induce detectable priming or significant anti-tumor activity of CTL using either vaccination strategy, whereas control SCT (with an exogenous peptide) primed strong responses. This study thus provides the first data related to the use of SCT in combination with DC and their application toward self antigens and suggest this potent technology, alone, is insufficient to overcome self tolerance.

Original languageEnglish (US)
Pages (from-to)141-149
Number of pages9
JournalCellular Immunology
Volume262
Issue number2
DOIs
StatePublished - Mar 3 2010

Keywords

  • B16
  • Dendritic cell
  • Gene Gun
  • MHC-I
  • Melanoma
  • Single-chain trimer
  • Tumor antigen
  • Tyrosinase-related protein

ASJC Scopus subject areas

  • Immunology

Fingerprint Dive into the research topics of 'DC-expressed MHC class I single-chain trimer-based vaccines prime cytotoxic T lymphocytes against exogenous but not endogenous antigens'. Together they form a unique fingerprint.

  • Cite this